Sai Life Sciences Q3 FY26: 34% EBITDA, revenue +27%

What changed in Q3 FY26

Sai Life Sciences Ltd. (Sai), an integrated Contract Research, Development and Manufacturing Organization (CRDMO), reported strong operating performance for the quarter ended December 2025 (Q3 FY26). Revenue from operations increased 27% year-on-year to ₹556 crore from ₹440 crore in Q3 FY25, supported by momentum across both the contract research organisation (CRO) and contract development and manufacturing organisation (CDMO) segments. EBITDA rose 54% year-on-year to ₹191 crore from ₹124 crore, while EBITDA margin expanded to 34% from 28%. Profit after tax (PAT) climbed to ₹100 crore from ₹54 crore, translating into an 86% year-on-year increase. PAT margin improved to 18% from 12% in the year-ago quarter.

Margin performance moved ahead of prior guidance

The margin outcome in Q3 FY26 stood out against the company’s stated long-term targets. In Q3 FY25, the CFO had outlined a goal to achieve a “steady-state EBITDA margin of 28-30% within the next 2-3 years.” One year later, the company reported a 34% EBITDA margin for Q3 FY26, with margin expansion of 605 basis points year-on-year. The Q3 FY26 investor presentation also noted that the 9M FY26 EBITDA margin reached 30%, effectively meeting the long-term target range ahead of schedule. Management attributed the improvement to higher capacity utilization, operational efficiencies, and ongoing cost optimization initiatives.

Nine-month numbers show faster scaling

For the nine months ended December 31, 2025 (9M FY26), Sai reported revenue from operations of ₹1,590 crore, up 43% from ₹1,115 crore in 9M FY25. EBITDA for 9M FY26 increased 79% to ₹472 crore from ₹264 crore, with EBITDA margin expanding to 30% from 24%. PAT surged 199% to ₹245 crore from ₹82 crore over the same period. The nine-month performance matters because it shows that the margin expansion is not limited to a single quarter.

Segment mix: CDMO led, CRO also grew

Sai said growth in Q3 FY26 was broad-based across service lines. The CDMO segment remained the larger contributor, generating ₹361.4 crore in Q3 FY26, around 65% of total revenue. The company’s commentary indicated that CDMO growth was supported by a robust commercial pipeline and the addition of seven late-phase and commercial molecules in 9M FY26. The CRO segment delivered ₹194.6 crore in Q3 FY26, around 35% of revenue, with growth linked to momentum in discovery programs and large pharma engagements. The company described both segments as contributors to the quarter’s volume-led growth.

Operating levers cited: utilization, efficiency, and a one-off tailwind

In its disclosures, Sai highlighted improved capacity utilization, operational efficiencies, and cost optimization as key drivers of margin expansion. It also reported a ₹16 crore provision reversal that supported profitability in Q3 FY26, alongside operating leverage on employee costs, which was described as contributing a 450 basis point benefit. The company reported current capacity utilization at 60%, indicating headroom for growth before new capacity commissioning. Lower interest costs were also referenced in the broader material, consistent with a deleveraged balance sheet.

Capex and quality milestones during the quarter

Sai said it has invested ₹405 crore in capital expenditure so far in FY26, against a planned capex outlay of ₹700 crore for the year. The company positioned this spending as aligned with long-term strategy to strengthen capabilities and expand capacity. On the quality front, Sai reported completing eight customer audits across its manufacturing and R&D units, with zero data integrity deviations and no critical observations. It also disclosed My Green Lab Green-level certification for four laboratories.

Track record: margin recovery since FY22

The company’s disclosures provide a clear historical context for the margin trajectory. Sai has scaled EBITDA margin from a low of 15% in FY22 to 25% in FY25, and to 30%+ levels in FY26, citing operating leverage and improved capacity utilization. The metric table shared in the material also shows steady improvement in PAT margins from 1% in FY22 to 10% in FY25 and 14% in H1 FY26. Working capital and inventory cycles were also shown as improving over time, alongside deleveraging.

Key numbers at a glance

Market impact: what investors typically focus on from these numbers

The combination of 27% year-on-year quarterly revenue growth and a step-up in EBITDA margin to 34% changes the near-term profitability profile implied by earlier guidance. The nine-month EBITDA margin of 30% is notable because it aligns with the previously articulated 28-30% steady-state target, but achieved sooner than the 2-3 year window mentioned earlier. Investors also tend to track the capex runway, given the ₹700 crore FY26 plan and the ₹405 crore spent through Q1-Q3 FY26. Segment contribution matters as well, with CDMO at about 65% of revenue in Q3 FY26 and CRO at about 35%, shaping expectations around revenue mix and execution visibility.

Analysis: the two watchpoints alongside strong growth

Two elements in the material warrant close monitoring even as results improved. First, the business is described as lumpy, and the company also references “completion-based” revenue recognition, which can create quarter-to-quarter variability in reported growth rates. Second, part of the Q3 FY26 margin benefit was supported by a ₹16 crore provision reversal, which investors typically treat as a non-operating tailwind when assessing steady-state profitability. These factors do not negate the operational progress, but they can matter when evaluating sustainability of margins and the timing of revenue conversion.

Conclusion

Sai Life Sciences’ Q3 FY26 results show revenue growth to ₹556 crore and EBITDA margin expansion to 34%, while 9M FY26 EBITDA margin reached 30%, meeting the earlier 28-30% target range ahead of schedule. The company continues to invest, with ₹405 crore capex incurred against a ₹700 crore FY26 plan, and it reported eight customer audits with zero critical observations. Sai has also scheduled an earnings call on February 6, 2026, at 4:00 PM IST to discuss the quarter’s performance and business updates.